Enpatoran, a TLR7/8 inhibitor, demonstrated clinically meaningful improvements in disease activity among patients with ...

Merck, a leading science and technology company, today announced the presentation of detailed results from Cohort B of the global Phase 2 WILLOW study (NCT05162586) evaluating enpatoran, an ...

The US Food and Drug Administration (FDA) has approved GSK's 200 mg/ml autoinjector of Benlysta for individuals aged five ...

Treatment of systemic lupus erythematosus needs to fulfill a number of objectives Symptoms of systemic lupus erythematosus (SLE) must be brought under control to avert immediate consequences and ...

Patients with systemic lupus erythematosus who received autologous chimeric antigen receptor T-cell therapy enjoyed potent ...

DelveInsight's BAFF- and APRIL-targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast ...

DelveInsight's "Systemic Lupus Erythematosus Pipeline Insight, 2025" report delivers comprehensive insights about 120+ companies and 140+ pipeline drugs currently in the various s ...

Halsey posted a selfie with a port in their chest on Instagram on Sunday, June 22. The singer shared their diagnosis of ...

T-cell therapy for rheumatologic disease is now expanding out of academe into the commercial space, with encouraging new data ...

Belimumab is now the first and only subcutaneous biologic therapy approved for at-home administration in pediatric lupus nephritis.

One year of treatment with dapirolizumab pegol reduced fatigue and disease activity in people with SLE in a Phase 3 trial.

Objective This study aims to evaluate the role of antiphospholipid antibodies (aPLs) in patients with SLE with heart valve ...